Abstract Metastatic struma ovarii is an extremely rare disease, and the treatment of choice has not been established. Here, we introduce the case of a 36-year-old female pregnant patient with metastatic struma ovarii. Initial treatment was an exploratory laparotomy to remove multiple peritoneal masses. After delivery, a total thyroidectomy was done for the further 131 I-therapy. 
Introduction
Struma means goiter, and struma ovarii is defined as an ovarian tumor with thyroid tissue comprising more than 50 % of the overall mass [1, 2] . Most commonly, it is a part of a teratoma; among them, malignant transformation occurs rarely. In fact, struma ovarii accounts for only 2 % of all teratomas, and malignant struma ovarii has been reported in less than 5-37 % of all cases of struma ovarii [3] . Until now, the the characteristics of malignant struma ovarii have not been evaluated well because of its rarity.
Post-surgical 131 I and retinoic acid combination therapy has been recommended for differentiated thyroid cancer including metastases and refractory-papillary thyroid cancer [4] [5] [6] . 131 I-SPECT/CT can easily be used to localize 131 I-avid metastases and evaluate the therapy response to radioiodine [7, 8] . Meanwhile, whole-body 18 F-FDG PET/CT has been widely implemented in various cancers using the increased glucose metabolism. However, the metabolic characteristics of malignant struma ovarii have not been evaluated.
Here, we report a patient with malignant struma ovarii in whom 131 I and retinoic acid combination therapy using 131 I-SPECT/CT and 18 F-FDG PET/CT was implemented. These modalities and therapy were very effective for the treatment and follow-up.
Case Report
A 36-year-old pregnant woman complained of multiple pelvic masses. She was admitted to the outside hospital and had an exploratory laparotomy to remove multiple peritoneal masses. She had been previously healthy and had no significant illness. There was no history of smoking or alcohol consumption. After delivery, a total thyroidectomy was done for the further 131 I-therapy in the outside hospital, and there was no thyroid cancer. The patient underwent five radioiodine therapies. After the first 131 I ablation therapy (30 mCi), 131 I-SPECT/CT showed increased radioiodine uptake in huge hepatic metastases and multiple peritoneal seeding lesions (Fig. 1) . The serum Tg level after TSH stimulation was 28,890 ng/ml.
18 F-FDG PET/CT was performed 1 month later, which showed huge hepatic metastases with increased FDG uptake and several FDG-avid peritoneal seeding lesions (Fig. 2) . The distribution of FDG uptake was different from that of radioiodine uptake. I-SPECT/CT, innumerable peritoneal seedings with avid iodine uptake were visualized in the perihepatic and subhepatic areas and pelvic cavity (Fig. 3) . The serum Tg level after TSH stimulation was 165.3 ng/ml. However, PET/CT performed 2 weeks later showed only minimal uptake in several peritoneal seeding nodules. Therefore, the 131 I whole-body scan and 131 I-SPECT/CT were useful to evaluate the remnant peritoneal seedings.
A third
131
I therapy combined with retinoic acid (200 mCi) was performed. The radioiodine whole-body scan shows a further decrease in the number and uptake amount of seeding nodules. The serum Tg level declined to 68.6 ng/ml after TSH stimulation. A fourth 131 I therapy (200 mCi) was performed. I-SPECT/CT show matched physiologic bowel uptake in the upper row and faint uptake in the previous seeding lesions in the pelvic cavity in the middle and lower row (white arrow). There was no significant lesion with avid iodine uptake. The patient showed a markedly improved state Faint uptake in a few peritoneal seeding lesions is visualized on the 131 I-SPECT/CT. A further decrease in the stimulated Tg is observed (39.2 ng/ml). A fifth posttherapy 131 I-SPECT/CT showed no significant uptake in the abdominopelvic cavity. The serum Tg level did not change significantly (42.3 ng/ml). There was only physiologic bowel uptake (Fig. 4) . During the 4-year followup, the patient had five 131 I therapies, four times with retinoid acid. The size and metabolic intensity of the metastatic lesions had decreased. Right now, the serum Tg level without TSH stimulation is 2.83 ng/ml. The serum Tg level according to 131 I therapy is summarized in Table 1 .
Discussion
Malignant struma ovarii is a very rare disease [9] [10] [11] [12] . The clinical course of extraovarian spread and the gold standard therapy have not been fully established. Here we report the disease characteristics using 131 I-SPECT/CT and 18 F-FDG PET/CT and the successful clinical outcome of a patient with malignant struma ovarii after 131 I therapy and the use of retinoic acid.
The typical treatments of malignant struma ovarii are radioiodine therapy following surgical resection. The surgery for malignant struma ovarii varies from unilateral oophorectomy to total abdominal hysterectomy and bilateral salpingooophorectomy with omentectomy. Malignant struma ovarii has similar morphological features as well-differentiated thyroid carcinoma. Therefore, the therapy and follow-up should be based on well-differentiated thyroid cancer. Radioiodine therapy is a well-known treatment for well-differentiated thyroid cancer; it reduces the recurrence and mortality rate at 20 years after 131 I therapy compared to the untreated group [13] , and it is the treatment of choice for malignant struma ovarii [2] . One important point is that total thyroidectomy should be performed before radioiodine treatment [1, 14] because of high avidity of radioiodine to normal thyroid compared to metastatic lesions.
In this study, the patient had multiple large hepatic metastases and peritoneal seedings. The metastatic lesions showed high radioiodine uptake and variable FDG uptake. This might represent the metabolic heterogeneity of metastases from thyroid cancer.
131
I therapy combined with retinoic acid showed good treatment response in this patient. Previously, we reported that a high response rate of this combination therapy is expected in young patients. Therefore, the successful treatment with 131 I therapy could be combined with the benefits of retinoic acid in this case. After the removal of hepatic metastases, the 131 I whole-body scan and 131 I-SPECT/CT images showed higher iodine-avid uptake in the multiple peritoneal seedings. This might be because of the redistribution of radioiodine and also the redifferentiation from the retinoic acid treatment. This patient experienced no significant side effects from the retinoic acid and had a good clinical course. Compared to previous reports [1, 15] , this patient demonstrated extensive metastatic lesions. This patient improved markedly after 131 I and retinoic acid combination therapy.
I-SPECT/CT and 18 F-FDG PET/CT were helpful for evaluating and comparing the characteristics of malignant struma ovarii. Metastases with high FDG uptake were removed by surgery, and metastases with high iodine uptake improved markedly with repeated 131 I combined with retinoic acid therapy. Therefore, we recommend using dual modalities for the treatment of malignant struma ovarii.
